About Phase 3 RRx-001

A new class of anti-cancer therapy with the potential to convert “treatment-resistant” tumors into “treatment sensitive” tumors

First-generation therapies, which target “checkpoint inhibitors”, have revolutionized the treatment of cancer, but only a small set of patients derives benefit. One of the reasons that not all patients respond to treatment is the presence of myeloid-derived suppressor cells in the tumor microenvironment.

Multimechanistic RRx-001 is a first-in-class small molecule immunotherapeutic that targets the CD47 – SIRPα axis and repolarizes tumor associated macrophages (TAMs) and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype.

RRx-001 can be used as monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy as an anti-cancer therapy, which also protects normal tissues.

RRx-001 was recently granted orphan drug designation for SCLC and neuroendocrine cancer in the US by the FDA and for SCLC in Europe by the EMA.

EpicentRx is currently enrolling patients with advanced small cell carcinoma to a Phase 3 clinical trial called REPLATINUM, investigating the activity and safety of RRx-001 in combination with platinum doublet chemotherapy versus platinum chemotherapy alone.

For a full list of currently enrolling clinical trials featuring RRx-001 please visit our Clinical Trials page.

For further information about RRx-001 mechanism of action and research please refer to our publications page.

For general inquiries about RRx-001, please contact us at info@epicentrx.com.